Progress in the development of fatty acid synthase inhibitors as anticancer targets

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4363-9. doi: 10.1016/j.bmcl.2015.08.087. Epub 2015 Sep 2.

Abstract

Fatty acid synthase (E.C. 2.3.1.85; FASN) is a multifunctional enzyme system that catalyzes the formation of fatty acids from acetyl-CoA, malonyl-CoA, and NADPH and plays a central role in lipid biosynthesis. Two classes of FASN exist: FASN I in animals and fungi, and FASN II in plants and prokaryotes. Animal FASN I is a homodimeric protein found in the cytosol of lipogenic tissues such as the liver and brain. Many human carcinomas exhibit elevated levels of FASN I, though the benefit to cancer cells is still unclear. Inhibition of FASN I selectively effects apoptosis in cancer cells, and the role of FASN I in chemotherapy is a growing area of research with the use of natural products and small molecule inhibitors.

Keywords: Anticancer; Fatty acid synthase; Inhibitors; Natural products.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Fatty Acid Synthase, Type I / antagonists & inhibitors*
  • Fatty Acid Synthase, Type I / metabolism
  • Fatty Acid Synthesis Inhibitors / chemistry
  • Fatty Acid Synthesis Inhibitors / pharmacology*
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Fatty Acid Synthesis Inhibitors
  • Fatty Acid Synthase, Type I